[저자] Jacob A. Dillard, Sharon A. Taft-Benz, Audrey C. Knight, Elizabeth J. Anderson, Katia D. Pressey, Breantié Parotti, Sabian A. Martinez, Jennifer L. Diaz, Sanjay Sarkar, Emily A. Madden, Gabriela De la Cruz, Lily E. Adams, Kenneth H. Dinnon, Sarah R. Leist, David R. Martinez, Alexandra Schäfer, John M. Powers, Boyd L. Yount, Izabella N. Castillo, Noah L. Morales, Jane Burdick, Mia Katrina D. Evangelista, Lauren M. Ralph, Nicholas C. Pankow, Colton L. Linnertz, Premkumar Lakshmanane, Stephanie A. Montgomery, Martin T. Ferris, Ralph S. Baric, Victoria K. Baxter, Mark T. Heise
[Category] update2024,
[Article Type] Article
[Source] PMC
Here, Dillard and Taft-Benz et al. show in a female mouse model how different adjuvants affect inactivated vaccine-mediated protection against homologous SARS-CoV-2 and heterologous SARS-CoV-1-like coronaviruses. They find that an aluminum hydroxide-adjuvanted vaccine can increase risk of adverse outcomes during heterologous infection.
All Keywords
【저자키워드】 SARS-CoV-2, Inactivated Vaccines, adjuvants, SARS virus,